New Developments in Platelet Cyclic Nucleotide Signalling: Therapeutic Implications
- 385 Downloads
Altered platelet physiology may contribute to the emergence of thrombosis in patients with many forms of cardiovascular disease. Excess platelet activation may reflect increased stimulation of pro-aggregatory pathways. There is, however, increasing evidence that excessive platelet response, due to impaired efficacy of anti-aggregatory autacoids such as nitric oxide (NO) and prostacyclin (PGI2), may be just as important. For example, diminished platelet response to NO has been documented in acute and chronic myocardial ischaemia, heart failure, aortic valve disease and in the presence of hyperglycaemia. This “NO resistance” has been shown to reflect both the scavenging of NO by reactive oxygen species and dysfunction of its intracellular “receptor”, soluble guanylate cyclase. Importantly, these abnormalities of NO signalling are potentially reversible through judicious application of pharmacotherapy. The analogous condition of impaired PGI2/adenylate cyclase (AC) signalling has received comparatively less attention to date. We have shown that platelet response to prostaglandin E1 (PGE1) is frequently impaired in patients with symptomatic myocardial ischaemia. Because the effects of ADP receptor antagonists such as clopidogrel and ticagrelor at the level of the P2Y12 receptor are coupled with changes in activity of AC, impaired response to PGE1 might imply both increased thrombotic risk and a reduced efficacy of anti-aggregatory drugs. Accordingly, patient response to treatment with clopidogrel is determined not only by variability of clopidogrel bio-activation, but also extensively by the integrity of platelet AC signalling. We here review these recent developments and their emerging therapeutic implications for thrombotic disorders.
KeywordsPlatelet Adenylate cyclase Soluble guanylate cyclase Prostacyclin Nitric oxide Clopidogrel
N.L. Hurst, H. Imam and V.B. Nooney were supported in part by postgraduate research fellowships from The University of Adelaide and The University of South Australia.
- 9.Procter NE, Ball J, Liu S, Hurst N, Nooney VB, Goh V et al. Impaired platelet nitric oxide response in patients with new onset atrial fibrillation. Int J Cardiol 2015;179(0):160–165.Google Scholar
- 11.Worthley MI, Holmes AS, Willoughby SR, Kucia AM, Heresztyn T, Stewart S, et al. The deleterious effects of hyperglycemia on platelet function in diabetic patients with acute coronary syndromes mediation by superoxide production, resolution with intensive insulin administration. J Am Coll Cardiol. 2007;49(3):304–10.CrossRefPubMedGoogle Scholar
- 18.Stepien JM, Prideaux RM, Willoughby SR, Chirkov YY, Horowitz JD. Pilot study examining the effect of cholesterol lowering on platelet nitric oxide responsiveness and arterial stiffness in subjects with isolated mild hypercholesterolaemia. Clin Exp Pharmacol Physiol. 2003;30(7):507–12.CrossRefPubMedGoogle Scholar
- 27.Ignarro LJ, Degnan JN, Baricos WH, Kadowitz PJ, Wolin MS. Activation of purified guanylate cyclase by nitric oxide requires heme. Comparison of heme-deficient, heme-reconstituted and heme-containing forms of soluble enzyme from bovine lung. Biochim Biophys Acta. 1982;718(1):49–59.CrossRefPubMedGoogle Scholar
- 46.Bliden KP, DiChiara J, Tantry US, Bassi AK, Chaganti SK, Gurbel PA. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? J Am Coll Cardiol. 2007;49(6):657–66.CrossRefPubMedGoogle Scholar
- 48.Aleil B, Jacquemin L, De Poli F, Zaehringer M, Collet JP, Montalescot G, et al. Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (vasodilator-stimulated phosphoprotein-02) randomized study. J Am Coll Cardiol Intv. 2008;1(6):631–8.CrossRefGoogle Scholar
- 51.Frelinger 3rd AL, Bhatt DL, Lee RD, Mulford DJ, Wu J, Nudurupati S, et al. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function. J Am Coll Cardiol. 2013;61(8):872–9.CrossRefPubMedGoogle Scholar
- 53.Nooney VB, Hurst NL, Chirkov YY, De Caterina R, Horowitz JD. Post receptor determinants of acute platelet response to clopidogrel in patients with symptomatic myocardial ischemia. Vasc Pharmacol 2015;65–66:17–22.Google Scholar
- 56.Michelson AD. Platelets. 2nd ed. Amsterdam. Boston: Academic Press/Elsevier; 2007.Google Scholar